Progyny (NASDAQ:PGNY) Releases Q1 2025 Earnings Guidance

Progyny (NASDAQ:PGNY) updated its first quarter 2025 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 0.440-0.470 for the period, compared to the consensus estimate of 0.400. The company issued revenue guidance of $300.0 million-$318.0 million, compared to the consensus revenue estimate of $280.5 million. Progyny also updated its FY 2025 guidance to 1.520-1.620 EPS.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. Bank of America upped their price objective on shares of Progyny from $21.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday, February 11th. Barclays decreased their price target on shares of Progyny from $30.00 to $17.00 and set an “overweight” rating for the company in a report on Thursday, November 14th. Canaccord Genuity Group lifted their price objective on Progyny from $17.00 to $23.00 and gave the stock a “hold” rating in a research note on Friday. JPMorgan Chase & Co. increased their target price on Progyny from $17.00 to $23.00 and gave the company a “neutral” rating in a research note on Tuesday, January 28th. Finally, Truist Financial reaffirmed a “hold” rating and issued a $19.00 target price (down previously from $26.00) on shares of Progyny in a report on Wednesday, November 13th. Nine investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, Progyny has an average rating of “Hold” and a consensus target price of $24.82.

Progyny Trading Down 1.5 %

PGNY opened at $22.53 on Friday. The stock has a market cap of $1.92 billion, a PE ratio of 38.85, a P/E/G ratio of 2.39 and a beta of 1.34. Progyny has a 1 year low of $13.39 and a 1 year high of $38.98. The stock’s 50 day simple moving average is $20.68 and its 200-day simple moving average is $18.69.

Insider Activity

In related news, Chairman David J. Schlanger acquired 150,000 shares of the stock in a transaction on Thursday, December 26th. The stock was purchased at an average price of $14.68 per share, for a total transaction of $2,202,000.00. Following the transaction, the chairman now owns 228,269 shares of the company’s stock, valued at $3,350,988.92. The trade was a 191.65 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Peter Anevski bought 209,500 shares of Progyny stock in a transaction dated Monday, December 23rd. The shares were bought at an average price of $14.48 per share, for a total transaction of $3,033,560.00. Following the completion of the transaction, the chief executive officer now directly owns 441,463 shares of the company’s stock, valued at $6,392,384.24. This represents a 90.32 % increase in their position. The disclosure for this purchase can be found here. 12.30% of the stock is owned by corporate insiders.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.